Is the CONUT score a prognostic index in multiple myeloma?

Eda Nilufer Coskun; Gulsum Akgun Cagliyan

Makale detayları

Is the CONUT score a prognostic index in multiple myeloma?

Yazarlar:

Eda Nilufer Coskun | Gulsum Akgun Cagliyan

Yayıncı:

Pamukkale University

Ana Başlıklar:

Hematoloji

Dergi:

Pamukkale Tıp Dergisi Vol.18 Issue 3, pp.628-636

Belge Tipi:

Makale

Yayın Tarihi:

2/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001329366

pISSN:

1308-0865

Anahtar kelimeler:

Özet:

 patients with multiple myeloma MM. Materials and methods: Our study was designed retrospectively. We calculated the CONUT score based on serum albumin, total cholesterol and lymphocytes. The study included 213 patients; 99 46.5 were female and 114 53.5 were male. The median follow-up period was 38 months 1-161. Results: The median age was 64 years. We participated the patients into four groups. It was defined as CONUT scores: normal 0-1, low 2-4, moderate 5-8, and high 9-12. We found significant differences between overall survival OS and progression-free survival PFS with regard to CONUT score, respectively, as high OS:12, PFS:1 months, moderate OS:27, PFS:13 months and low OS:54, PFS:28 months p0.001 and p0.001. In the multivariate analysis for OS, having moderate CONUT score HR: 2.21, p0.005 and high CONUT score HR: 2.38, p0.033 were increased the risk of mortality. In the multivariate analysis for PFS, compared to a normal CONUT score, a moderate CONUT score HR: 1.85, p0.007, and a high CONUT score HR: 2.01, p0.043 were found to increase the risk of progression. Conclusion: We found that a high CONUT score is related to decreased OS and PFS. In our study, we showed that the CONUT score is an independent, useful and strong prognostic index in MM.

 patients with multiple myeloma MM. Materials and methods: Our study was designed retrospectively. We calculated the CONUT score based on serum albumin, total cholesterol and lymphocytes. The study included 213 patients; 99 46.5 were female and 114 53.5 were male. The median follow-up period was 38 months 1-161. Results: The median age was 64 years. We participated the patients into four groups. It was defined as CONUT scores: normal 0-1, low 2-4, moderate 5-8, and high 9-12. We found significant differences between overall survival OS and progression-free survival PFS with regard to CONUT score, respectively, as high OS:12, PFS:1 months, moderate OS:27, PFS:13 months and low OS:54, PFS:28 months p0.001 and p0.001. In the multivariate analysis for OS, having moderate CONUT score HR: 2.21, p0.005 and high CONUT score HR: 2.38, p0.033 were increased the risk of mortality. In the multivariate analysis for PFS, compared to a normal CONUT score, a moderate CONUT score HR: 1.85, p0.007, and a high CONUT score HR: 2.01, p0.043 were found to increase the risk of progression. Conclusion: We found that a high CONUT score is related to decreased OS and PFS. In our study, we showed that the CONUT score is an independent, useful and strong prognostic index in MM.

 patients with multiple myeloma MM. Materials and methods: Our study was designed retrospectively. We calculated the CONUT score based on serum albumin, total cholesterol and lymphocytes. The study included 213 patients; 99 46.5 were female and 114 53.5 were male. The median follow-up period was 38 months 1-161. Results: The median age was 64 years. We participated the patients into four groups. It was defined as CONUT scores: normal 0-1, low 2-4, moderate 5-8, and high 9-12. We found significant differences between overall survival OS and progression-free survival PFS with regard to CONUT score, respectively, as high OS:12, PFS:1 months, moderate OS:27, PFS:13 months and low OS:54, PFS:28 months p0.001 and p0.001. In the multivariate analysis for OS, having moderate CONUT score HR: 2.21, p0.005 and high CONUT score HR: 2.38, p0.033 were increased the risk of mortality. In the multivariate analysis for PFS, compared to a normal CONUT score, a moderate CONUT score HR: 1.85, p0.007, and a high CONUT score HR: 2.01, p0.043 were found to increase the risk of progression. Conclusion: We found that a high CONUT score is related to decreased OS and PFS. In our study, we showed that the CONUT score is an independent, useful and strong prognostic index in MM.

 Amaç: Multiple Myelom MM hastalarında CONUT skorunun prognoza etkisini değerlendirmeyi amaçladık. Gereç ve yöntem: Çalışmamız retrospektif bir çalışma olarak tasarlandı. CONUT skorunu serum albumin, total kolesterol ve lenfosit değerlerine göre hesapladık. Bu çalışmaya 99u 46,5 kadın, 114ü 53,5 erkek olmak üzere 213 hasta dahil edildi. Median takip süresi 38 ay idi 1-161. Bulgular: Median yaş 64 idi. Hastaları CONUT skoruna göre dört gruba ayırdık: normal 0-1, düşük 2-4, orta 5-8 ve yüksek 9-12. CONUT skoruna göre genel sağkalım OS ve progresyonsuz sağkalım PFS arasında sırasıyla yüksek OS:12, PFS:1 ay, orta OS:27, PFS:13 ay ve düşük OS:54, PFS:28 ay anlamlı farklar bulduk p0,001 ve p0,001. OS için yapılan çok değişkenli analizde CONUT skorunun orta düzeyde olması 2,21 kat HR:2,21, p0,005, CONUT skorunun yüksek olması 2,38 kat HR:2,38, p0,033 mortalite riskini arttırıyordu. PFS için yapılan çok değişkenli analizde normal CONUT düzeyiyle karşılaştırıldığında orta derecede CONUT skorunun HR:1,85, p0,007, yüksek CONUT skorunun HR:2,01, p0,043 ilerleme riskini arttırdığı belirlendi. Sonuç: Yüksek CONUT skorunun OS ve PFSde azalma ile ilişkili olduğunu belirledik. Çalışmamızda CONUT skorunun MMda bağımsız, güçlü bir prognostik indeks olduğunu gösterdik.

Makale detayları

Is the CONUT score a prognostic index in multiple myeloma?

Yazarlar:

Eda Nilufer Coskun | Gulsum Akgun Cagliyan

Yayıncı:

Pamukkale University

Ana Başlıklar:

Hematoloji

Dergi:

Pamukkale Tıp Dergisi Vol.18 Issue 3, pp.628-636

Belge Tipi:

Makale

Yayın Tarihi:

2/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001329366

pISSN:

1308-0865

CONUT score

multiple myeloma

survival

prognosisCONUT skor

multipl myelom

sağkalım

prognoz

Sayı

Makale detayları

Yazarlar: Eda Nilufer Coskun | Gulsum Akgun Cagliyan

Yayıncı: Pamukkale University

Ana Başlıklar: Hematoloji

Dergi: Pamukkale Tıp Dergisi Vol.18 Issue 3, pp.628-636

Belge Tipi: Makale

Yayın Tarihi: 2/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001329366

pISSN: 1308-0865

Sayı

Yazarlar:

Eda Nilufer Coskun | Gulsum Akgun Cagliyan

Yayıncı:

Pamukkale University

Ana Başlıklar:

Hematoloji

Dergi:

Pamukkale Tıp Dergisi Vol.18 Issue 3, pp.628-636

Belge Tipi:

Makale

Yayın Tarihi:

2/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001329366

pISSN:

1308-0865